Logo image of INTS

INTENSITY THERAPEUTICS INC (INTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INTS - US45828J1034 - Common Stock

0.3993 USD
-0.01 (-2.2%)
Last: 1/20/2026, 8:00:02 PM
0.4 USD
+0 (+0.18%)
After Hours: 1/20/2026, 8:00:02 PM
Fundamental Rating

2

Overall INTS gets a fundamental rating of 2 out of 10. We evaluated INTS against 525 industry peers in the Biotechnology industry. The financial health of INTS is average, but there are quite some concerns on its profitability. INTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • INTS had negative earnings in the past year.
  • In the past year INTS has reported a negative cash flow from operations.
  • In the past 5 years INTS always reported negative net income.
  • INTS had a negative operating cash flow in each of the past 5 years.
INTS Yearly Net Income VS EBIT VS OCF VS FCFINTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -122.44%, INTS is doing worse than 78.86% of the companies in the same industry.
  • INTS's Return On Equity of -162.50% is on the low side compared to the rest of the industry. INTS is outperformed by 65.33% of its industry peers.
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROIC N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INTS Yearly ROA, ROE, ROICINTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

  • INTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INTS Yearly Profit, Operating, Gross MarginsINTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

  • INTS has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for INTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INTS Yearly Shares OutstandingINTS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
INTS Yearly Total Debt VS Total AssetsINTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • INTS has an Altman-Z score of -8.18. This is a bad value and indicates that INTS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -8.18, INTS is doing worse than 68.38% of the companies in the same industry.
  • INTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.18
ROIC/WACCN/A
WACCN/A
INTS Yearly LT Debt VS Equity VS FCFINTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • INTS has a Current Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
  • INTS's Current ratio of 3.60 is in line compared to the rest of the industry. INTS outperforms 43.24% of its industry peers.
  • INTS has a Quick Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
  • INTS has a Quick ratio (3.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
INTS Yearly Current Assets VS Current LiabilitesINTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.12% over the past year.
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, INTS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.79%
EPS Next 2Y34.63%
EPS Next 3Y19.7%
EPS Next 5Y15.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INTS Yearly Revenue VS EstimatesINTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
INTS Yearly EPS VS EstimatesINTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • INTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INTS Price Earnings VS Forward Price EarningsINTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INTS Per share dataINTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • INTS's earnings are expected to grow with 19.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.63%
EPS Next 3Y19.7%

More info and screens

0

5. Dividend

5.1 Amount

  • INTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INTENSITY THERAPEUTICS INC

NASDAQ:INTS (1/20/2026, 8:00:02 PM)

After market: 0.4 +0 (+0.18%)

0.3993

-0.01 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)N/A
Inst Owners4.96%
Inst Owner Change0%
Ins Owners7.59%
Ins Owner Change1.11%
Market Cap23.98M
Revenue(TTM)N/A
Net Income(TTM)-11.74M
Analysts80
Price Target2.98 (646.31%)
Short Float %3.4%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.12%
Min EPS beat(2)32.77%
Max EPS beat(2)35.47%
EPS beat(4)3
Avg EPS beat(4)15.34%
Min EPS beat(4)-10.61%
Max EPS beat(4)35.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)9.52%
EPS NQ rev (3m)42.42%
EPS NY rev (1m)1.47%
EPS NY rev (3m)25.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.32
P/tB 3.32
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -8.18
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y70.79%
EPS Next 2Y34.63%
EPS Next 3Y19.7%
EPS Next 5Y15.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.37%
OCF growth 3YN/A
OCF growth 5YN/A

INTENSITY THERAPEUTICS INC / INTS FAQ

What is the fundamental rating for INTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to INTS.


Can you provide the valuation status for INTENSITY THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to INTENSITY THERAPEUTICS INC (INTS). This can be considered as Overvalued.


How profitable is INTENSITY THERAPEUTICS INC (INTS) stock?

INTENSITY THERAPEUTICS INC (INTS) has a profitability rating of 0 / 10.


Can you provide the financial health for INTS stock?

The financial health rating of INTENSITY THERAPEUTICS INC (INTS) is 6 / 10.